Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.

Olaparib is the first poly(ADP-ribose) polymerase inhibitor approved as maintenance therapy of recurrent ovarian cancer (OC) patients with a BRCA mutation. To achieve the maximum clinical benefit, adherence to olaparib must be persistent. However, in clinical practice, this is challenged by the freq...

Full description

Bibliographic Details

Published in:	Supportive Care in Cancer Vol. 28; no. 5; pp. 2435 - 2443
Main Authors:	Lorusso, Domenica, Bologna, Alessandra, Cecere, Sabrina Chiara, De Matteis, Elisabetta, Scandurra, Giusy, Zamagni, Claudio, Arcangeli, Valentina, Artioli, Fabrizio, Bella, Mariangela, Blanco, Giusi, Cardalesi, Cinzia, Casartelli, Clelia, De Vivo, Rocco, Di Napoli, Marilena, Gisone, Emanuele Baldo, Lauria, Rossella, Lissoni, Alberto Andrea, Loizzi, Vera, Maccaroni, Elena, Mangili, Giorgia
Format:	Journal Article
Published:	Springer Nature May2020
Online Access:	View this record in EBSCOhost